Fenofibrate

證據等級: L5

預測適應症: 7 個

Fenofibrate: From Hyperlipidemia to Homozygous Familial Hypercholesterolemia

One-Sentence Summary

Fenofibrate is a fibrate-class lipid-lowering agent whose established use, per the literature in this evidence pack, is hyperlipidemia and mixed dyslipidemia (including fasting triglyceride reduction to prevent pancreatitis). The TxGNN model predicts it may also be effective for Homozygous Familial Hypercholesterolemia (HoFH), with 1 registered clinical trial and 11 publications currently associated with this indication — though only a subset of that literature studies fenofibrate directly in HoFH patients.

Quick Overview

Item	Content
Original Indication	Hyperlipidemia / Mixed Dyslipidemia (per literature evidence, e.g. PMID 37979722: fenofibrate monotherapy indicated for fasting TG >500 mg/dL)
Predicted New Indication	Homozygous Familial Hypercholesterolemia (HoFH)
TxGNN Prediction Score	99.91%
Evidence Level	L2 (1 completed Phase 3 RCT registered under this indication — but see caveat below)
Germany Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Caveat on Evidence Level: The single completed Phase 3 trial (NCT03510715) evaluates alirocumab, not fenofibrate, in HoFH. It was returned because it matches the disease term, not because it tests the candidate drug. Fenofibrate-specific evidence for HoFH in this pack is limited to one historical case series (PMID 6593751) describing a single HoFH patient.

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (DrugBank MOA field returned as Data Gap). Based on known information from the evidence pack, fenofibrate belongs to the fibrate class of lipid-lowering agents; its efficacy in hyperlipidemia and mixed dyslipidemia has been demonstrated across decades of literature, and mechanistically it may be applicable to genetic/familial cholesterol disorders such as HoFH.

HoFH and the other TxGNN-predicted indications in this pack (hyperlipoproteinemia, familial hypercholesterolemia, CETP deficiency, CYP7A1 deficiency, hepatic triglyceride lipase deficiency, autosomal dominant hypercholesterolemia) are not a departure from fenofibrate's known pharmacology — they are all genetic or rare subtypes within the same broader dyslipidemia disease family the drug already treats. This is reflected in the pack itself: multiple older studies (e.g., PMID 3924068, PMID 3829426, PMID 2918846) directly document fenofibrate's lipid-lowering effect in heterozygous FH patients, and one case series (PMID 6593751) includes a HoFH patient showing the greatest LDL-C reduction in the cohort.

The rationale therefore is less "novel repurposing" and more "TxGNN correctly recognizing a drug already active in an adjacent, more specific disease phenotype." However, dedicated prospective evidence of fenofibrate specifically in HoFH is thin — modern HoFH trials in this pack (alirocumab) reflect current standard-of-care shifting toward PCSK9 inhibitors and MTP inhibitors (e.g., lomitapide, PMID 24734312) rather than fibrate monotherapy, which is consistent with fenofibrate now serving as adjunct/triglyceride-focused therapy rather than a primary HoFH treatment.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03510715	Phase 3	Completed	18	Evaluates alirocumab (not fenofibrate) Q2W in children/adolescents (8–17y) with HoFH on top of background lipid-lowering treatment; assesses LDL-C reduction at 12, 24, 48 weeks. Included for disease-term relevance only — does not test fenofibrate directly.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
6593751	1984	Case series	Pharmacological Research Communications	22 type II hyperlipoproteinemic patients treated with fenofibrate 300mg/day; one HoFH patient showed the greatest fall in total and LDL cholesterol among the cohort.
24734312	2014	PK study	Pharmacotherapy	Characterizes PK interaction between lomitapide (MTP inhibitor approved for HoFH) and commonly co-administered lipid drugs including fenofibrate.
37979722	2024	Review	Indian Heart Journal	States fenofibrate's most definite monotherapy indication is fasting TG >500 mg/dL to prevent pancreatitis; positions fibrates among non-statin options.
2042836	1991	Review	Annals of the NY Academy of Sciences	Reviews pharmacologic treatments for dyslipidemic children with FH, including fenofibrate among successful regimens.
24946816	2014	Case report/Review	Internal Medicine Journal	Discusses liver transplantation for HoFH in the context of emerging lipid-lowering therapies; not fenofibrate-specific.
28437620	2017	Guideline	Endocrine Practice	AACE/ACE dyslipidemia management guidelines, general framework covering fibrate-class agents.
35499807	2022	Review	Current Atherosclerosis Reports	Reviews dyslipidemia management in pregnancy; tangential to HoFH.
26432726	2015	Review	Indian Heart Journal	Overview of LDL-C reduction strategies (statins, PCSK9i); general context, not fenofibrate-focused.
14620392	2003	Review	Pharmacotherapy	Reviews ezetimibe as a cholesterol absorption inhibitor; general dyslipidemia context, not fenofibrate-specific.
9129869	1997	Review	Drugs	Reviews atorvastatin pharmacology and therapeutic potential in hyperlipidaemia; general comparator context.

Germany Market Information

Fenofibrate currently holds no marketing authorizations in the German dataset used for this evidence pack (market_status: 未上市, total_licenses: 0). No product-level authorization records are available to summarize.

Safety Considerations

Please refer to the package insert for safety information. No key warnings, contraindications, or drug interaction data were available in this evidence pack (DG001: TFDA/BfArM label warnings and contraindications are a Blocking data gap — currently unable to complete an S1 safety pre-assessment).

Conclusion and Next Steps

Decision: Hold

Rationale: A Blocking-severity data gap (missing regulatory label safety/contraindication data) prevents any S1 safety pre-assessment, and the drug currently has zero marketing authorizations in Germany. In addition, the only Phase 3 trial associated with this indication tests a different drug (alirocumab), not fenofibrate — direct fenofibrate-specific evidence for HoFH is limited to a single 1984 case series.

To proceed, the following is needed:

TFDA/BfArM label data: warnings, contraindications, and DDI profile (resolve DG001, Blocking)
DrugBank MOA data to support mechanistic rationale (resolve DG002)
Clarification of fenofibrate's German regulatory/market status, given 0 current authorizations
Dedicated fenofibrate-specific clinical or observational evidence in HoFH (current standard of care has shifted toward PCSK9i/MTP inhibitors), to distinguish this from disease-term-matched but drug-mismatched trial evidence
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.